Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs.
Evidence has been accumulating for a link between Chlamydia pneumoniae and coronary heart disease (CHD). A spreadsheet model was used to estimate the impact of different strategies for screening and treating C. pneumoniae on the incidence of myocardial infarction and cardiac mortality over a 1-year post-intervention period. It was found that screening would potentially be most cost-effective in men aged over 35 with a history of myocardial infarction (around ł2,000 per life-year saved). Cost-effectiveness would be inferior in those with established heart disease but no history of myocardial infarction (MI), and poor for people at elevated risk of CHD. If causality of the association were proven, the cost-effectiveness of treating C. pneumoniae in post-MI patients would compare favourably with, for example, statins for treating hypercholesterolaemia.
Sanderson
C
C
Health Services Research Unit, London School of Hygiene and Tropical Medicine, UK. colin.sanderson@lshtm.ac.uk
Kubin
M
M
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D002690:Chlamydia Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000302:isolation & purification*; D003327:Coronary Disease / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
D000900:Anti-Bacterial Agents